Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Effect of Anti-Retroviral Drug Impurity/Related Substances on the CCR5 and/or CXCR4 Receptors Binding Sites to Revise Resistance Mechanisms in the Clinical Implications Using Molecular Docking Studies

Author(s): Rinchi Bora, M.R. Jeyaprakash* and S. Jubie

Volume 19, Issue 1, 2022

Published on: 22 December, 2021

Article ID: e140122192497 Pages: 14

DOI: 10.2174/1570163818666210329102901

Price: $65

Abstract

Background: CCR5 and/or CXCR4 receptors on CD4+ T cell membranes are the active sites for HIV to bind. The different classes of drugs have a unique mechanism of action to cease the virus, but we are concentrating in the first-class i.e. NNRTI that destroys the virus while it binds to the cell surface gp120 protein. The drugs are having several impurities that can be genotoxic and few are reported in the monographs.

Objective: This study proposes the affinity of the impurities to the active site through molecular docking to a receptor (PDB ID 4MBS) from the library of analogs available for antiretroviral drugs. As these drugs are taken for the long term, this study will give a prominent idea for testing the impurities and their genotoxicity.

Methods: We have done molecular docking of 37 impurities and drugs with the GLIDE module of schrodinger software for their binding affinities. In this study, receptor CCR5 and/or CXCR4 is selected containing glycoprotein that mediates virus binding to CD4+ T cell.

Results: Didanosine E and Zidovudine D shows maximum and minimum score respectively. The selected impurities were interfering with the active binding site that may lead to any ADR or reduce the effect of API.

Conclusion: Conclusively, a significant role is played by Protein-Ligand interaction in structuralbased designing. Summarizing that there might be a genotoxicity effect due to competition between API and the impurities. The molecular docking was used to study the binding mechanism and to establish the docking score along with the activity. The outcome of the study can be used to design and development of novel compounds having genotoxicity.

Keywords: CCR5, CXCR4, molecular-docking, NNRTI, affinity, impurities, 4MBS, genotoxicity.

[1]
Bhatti AB, Usman M, Kandi V. Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy. Cureus 2016; 8(3)e515
[http://dx.doi.org/10.7759/cureus.515] [PMID: 27054050]
[2]
HIV/AIDS.World Health Organization.. Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-aids
[3]
Global HIV/AIDS Overview. Available from: https://www.hiv.gov/federal-response/pepfar-global-aids/global-hiv-aids-overview
[4]
Williams BG, Lima V, Gouws E. Modelling the impact of antiretroviral therapy on the epidemic of HIV. Curr HIV Res 2011; 9(6): 367-82.
[http://dx.doi.org/10.2174/157016211798038533] [PMID: 21999772]
[5]
Report on the global HIV/AIDS epidemic–June. 1998. Available from: http://data.unaids.org/pub/report/1998/19981125_global _epidemic_report_en.pdf
[6]
World Health Organization Available from. https://www.who.int/research-observatory/analyses/hiv/en/
[7]
Weatherall D, Greenwood B, Chee HL, Wasi P. Science and Technology for Disease Control: Past, Present, and Future Disease control priorities in developing countries. 2nd ed. New York: Oxford University Press 2006; pp. 119-38.
[8]
https://www.slideshare.net/DrVijayBhushanam/vj-antiretroviral
[9]
Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012; 2(4)a007161
[http://dx.doi.org/10.1101/cshperspect.a007161] [PMID: 22474613]
[10]
Woodham AW, Skeate JG, Sanna AM, et al. Human immunodeficiency virus immune cell receptors, coreceptors, and cofactors: Implications for prevention and treatment. AIDS Patient Care STDS 2016; 30(7): 291-306.
[http://dx.doi.org/10.1089/apc.2016.0100] [PMID: 27410493]
[11]
Central Drugs Standard Control Organization Available from. https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTUyNw==
[12]
National List of Essential Medicines of India Available from. https://pharmaceuticals.gov.in/sites/default/files/NLEM.pdf
[13]
Dr Paula Munderi. ARV related toxicities, Nucleoside reverse transcriptase inhibitors (NRTIs) WHO training course for introducing, pharmacovigilance of HIV medicines 23 - 28 November Dar Es Salaam.. 2009.
[14]
British Pharmacopoeia, European Pharmacopoeia, Japanese Pharmacopoeia, Indian Pharmacopoeia, United States Pharmacopoeia. Index of pharmacopoeias Available from:https://www.who.int/medicines/publications/pharmacopoeia/WHOPSMQSM2006_2_IndexPharmacopoeias.pdf
[15]
Plošnik A. Vračko M, Dolenc MS. Mutagenic and carcinogenic structural alerts and their mechanisms of action. Arh Hig Rada Toksikol 2016; 67(3): 169-82.
[http://dx.doi.org/10.1515/aiht-2016-67-2801] [PMID: 27749264]
[16]
Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004; 3(11): 935-49.
[http://dx.doi.org/10.1038/nrd1549] [PMID: 15520816]
[17]
Halperin I, Ma B, Wolfson H, Nussinov R. Principles of docking: An overview of search algorithms and a guide to scoring functions. Proteins 2002; 47(4): 409-43.
[http://dx.doi.org/10.1002/prot.10115] [PMID: 12001221]
[18]
Coupez B, Lewis RA. Docking and scoring--theoretically easy, practically impossible? Curr Med Chem 2006; 13(25): 2995-3003.
[http://dx.doi.org/10.2174/092986706778521797] [PMID: 17073642]
[19]
Kontoyianni M, Madhav P, Suchanek E, Seibel W. Theoretical and practical considerations in virtual screening: a beaten field? Curr Med Chem 2008; 15(2): 107-16.
[http://dx.doi.org/10.2174/092986708783330566] [PMID: 18220766]
[20]
Brooijmans N, Kuntz ID. Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct 2003; 32: 335-73.
[http://dx.doi.org/10.1146/annurev.biophys.32.110601.142532] [PMID: 12574069]
[21]
Li X, Li Y, Cheng T, Liu Z, Wang R. Evaluation of the performance of four molecular docking programs on a diverse set of protein-ligand complexes. J Comput Chem 2010; 31(11): 2109-25.
[http://dx.doi.org/10.1002/jcc.21498] [PMID: 20127741]
[22]
Plewczynski D. Łaźniewski M, Augustyniak R, Ginalski K. Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database. J Comput Chem 2011; 32(4): 742-55.
[http://dx.doi.org/10.1002/jcc.21643] [PMID: 20812323]
[23]
McConkey BJ, Sobolev V, Edelman M. The performance of current methods in ligand-protein docking. Curr Sci 2002; 83: 845-55.
[24]
Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985; 28(7): 849-57.
[http://dx.doi.org/10.1021/jm00145a002] [PMID: 3892003]
[25]
Kastenholz MA, Pastor M, Cruciani G, Haaksma EE, Fox T. GRID/CPCA: a new computational tool to design selective ligands. J Med Chem 2000; 43(16): 3033-44.
[http://dx.doi.org/10.1021/jm000934y] [PMID: 10956211]
[26]
Levitt DG, Banaszak LJ. POCKET: a computer graphics method for identifying and displaying protein cavities and their surrounding amino acids. J Mol Graph 1992; 10(4): 229-34.
[http://dx.doi.org/10.1016/0263-7855(92)80074-N] [PMID: 1476996]
[27]
Laskowski RA. SURFNET: a program for visualizing molecular surfaces, cavities, and intermolecular interactions 1995; 13(5): 323-30.
[http://dx.doi.org/10.1016/0263-7855(95)00073-9] [PMID: 8603061]
[28]
Glaser F, Morris RJ, Najmanovich RJ, Laskowski RA, Thornton JM. A method for localizing ligand binding pockets in protein structures. Proteins 2006; 62(2): 479-88.
[http://dx.doi.org/10.1002/prot.20769] [PMID: 16304646]
[29]
Brady GP Jr, Stouten PF. Fast prediction and visualization of protein binding pockets with PASS. J Comput Aided Mol Des 2000; 14(4): 383-401.
[http://dx.doi.org/10.1023/A:1008124202956] [PMID: 10815774]
[30]
Perola E, Walters WP, Charifson PS. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 2004; 56(2): 235-49.
[http://dx.doi.org/10.1002/prot.20088] [PMID: 15211508]
[31]
Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006; 49(2): 534-53.
[http://dx.doi.org/10.1021/jm050540c] [PMID: 16420040]
[32]
Heena VS, Sunil HG, Rama P. Molecular – docking studies of potent anticancer agent J Comput Sci Syst Biol 2012; 5(1): 012-5.
[http://dx.doi.org/10.4172/jcsb.1000085]
[33]
Drug discovery and materials design Available from:https://www.schrodinger.com
[34]
Protein data Bank. Available from: https://www.rcsb.org/ structure/4MBS
[35]
FDA. Available from :https://www.accessdata.fda.gov/drugsatfda

Rights & Permissions Print Cite
Article Metrics
19
1
© 2024 Bentham Science Publishers | Privacy Policy